Mergers & Acquisitions
By The Online Investor Staff, updated Tue., Mar. 19, 12:21 AM
Slide #79. Aptorum Group Limited — YOOV Group Holding Ltd
Acquirer: |
Aptorum Group Limited (NASDAQ:APM) |
Acquiree: |
YOOV Group Holding Ltd |
Details: |
Aptorum Group Limited (NASDAQ:APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum's and YOOV's boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Aptorum's and YOOV's shareholders (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing", and the date of the Closing, the "Closing Date"), a wholly-owned subsidiary of Aptorum organized under the laws of the British Virgin Islands ("Merger Sub") will merge with and into YOOV (collectively, the "Merger"). |
Aptorum Group is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs. In addition, Co. is also pursuing in the therapeutic projects in neurology, gastroenterology, metabolic disorders, women's health and other disease areas. Co.'s Lead Projects are: ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus including but not limited to Methicillin-resistant Staphylococcus aureus; SACT-1, repurposed frug for the treatment of Neuroblastoma; and RPIDD, a molecular-based rapid pathogen identification and detection diagnostics technology.
Open the APM Page at The Online Investor »
Open the APM Page at The Online Investor (in a new window) »
|
March 19, 2024 12:21 AM Eastern
|